Antagonizing effects of YM-14673, a new TRH derivative,on behavioral and electroencephalographic changes in reserpinized animals

Effects of YM-14673 (N-[{(S)-4-oxo-2-azetidinyl}-carbonyl]-l-histidyl-l-prolinamide dihydrate), a new TRH derivative, on reserpine-induced behavioural and electroencephalographic changes were observed in comparison with those of TRH. YM-14673 antagonized reserpine-induced hypothermia and decrease in convulsion threshold in mice. The number of PGO waves recorded from the lateral geniculate body was decreased by administration of YM-14673 in reserpinized cats. The anti-reserpine activity of intravenous YM-14673 was about 8–20 times more potent than that of TRH. In inhibiting reserpine-induced hypothermia, the oral ED_2°C relative to IV ED_2°C as an indirect indication of absorption rate of the drugs was 15 for both YM-14673 and TRH. These results suggest that YM-14673 possesses more potent facilitatory effects on the central monoamine systems than TRH.     

Effects of a new TRH analogue,YM-14673 on a passive avoidance test as a possible criterion of improvement in cognitive disturbance in rodents

Summary Effects of a new TRH analogue, YM-14673 (N-[[(S)-4-oxo-2-azetidinyl carbonyl]-l-histidyl-L-prolinamide dihydrate) on cognitive disturbance of passive avoidance response were studied in rodents in comparison with those of TRH and CDP-choline. The latency for entering from the illuminated into the dark compartments was shortened in anoxia and scopolamine-treated rats, cycloheximidetreated mice and cerebral ischemic gerbils. The shortened latency in these models was prolonged by administration of both YM-14673 and TRH in doses without effect on spontaneous movement. YM-14673 was about 10 times more potent than TRH in ameliorating the cognitive disturbance, whereas CDP-choline showed no influence on the learning ability. These results suggest that YM-14673 and TRH possess facilitatory effects on cerebral function and that YM-14673 was distinct from CDP-choline in pharmacological profile. Send offprint requests to M. Yamamoto at the above address     

Central dopaminergic actions of YM-14673, a new TRH analogue, in rodents

The effects of a new TRH analogue, YM-14673 (N-[[(S)-4-oxo-2-azetidinyl]carbonyl]-L-histidyl-L-prolinamide dihydrate) on spontaneous movement, sniffing, climbing, licking, biting and circling behaviors were compared with those of TRH and methamphetamine, in rodents. YM-14673 in a dose of 1 mg/kg (i.p.) enhanced spontaneous motor activity in rats, and induced sniffing and climbing behaviors in mice. The licking and biting behaviors were not induced by administration of YM-14673 even in a high dose (30–100 mg/kg i.p.) to mice. In addition, ipsilateral circling did not follow the i.p. administration of YM-14673 in rats receiving cis-flupenthixol unilaterally into the striatum. YM-14673 was about 20–30 times more potent than TRH to induce sniffing and climbing behaviors and to increase spontaneous movement. The sniffing and climbing behaviors induced by administration of YM-14673 and TRH were antagonized by treatment with haloperidol and -methyl-para-tyrosine (-MT). Methamphetamine (0.5–10 mg/kg i.p.), unlike YM-14673, showed significant pharmacological effects in all behavioral experiments, so that the pharmacological profile of YM-14673 was different from that of methamphetamine. These results suggest that both YM-14673 and TRH induced behavioral changes, presumably due to facilitatory effects on the central dopaminergic system.     

Effects of a new analogue of thyrotropin-releasing hormone on pentobarbital-induced sleeping time in rodents

The effects of a new analogue of TRH, YM-14673 (N-[[(S)-4-oxo-2-azetidinyl]carbonyl]-L-histidyl-L-prolinamide dihydrate) on pentobarbital-sleeping time were observed in comparison with those of TRH in rodents. The YM-14673 was administered intravenously, orally and intramuscularly. In all cases it reduced pentobarbital-sleeping time in rats and/or mice in a dose-dependent manner. The analeptic activity of YM-14673 was about 10 times greater than that of TRH. Analeptic action was also observed with successive intravenous injections of YM-14673, once daily for 5 and 14 days in mice, suggesting that the drug induced no tolerance. In addition, there was evidence that the pituitary-thyroid axis was not necessary for the analeptic effects of YM-14673. In particular, it was noted that hypophysectomy did not reduce the antagonism by YM-14673 of pentobarbital-induced sleep and intracerebrally administered YM-14673 produced analeptic actions in mice. Pretreatment with atropine and baclofen antagonized the ability of YM-14673 to reduce sleep, induced by pentobarbital in mice. However, the analeptic action of YM-14673 was not reduced by the administration of haloperidol and phentolamine. These results suggest that YM-14673 produced facilitatory effects on the central nervous system, independent of an effect on the pituitary gland, and that the antagonizing effects by YM-14673 on the actions of pentobarbital may be affected by activation of the central cholinergic system as well as by inhibition of the GABA-ergic system.     

Effect of YM-14673, a new thyrotropin releasing hormone analogue, on ataxic gait in cytosine arabinoside-treated mice

The effect of YM-14673, a new thyrotropin releasing hormone (TRH) analogue, on ataxic gait in mice treated with cytosine arabinoside was observed and compared with the effect of TRH. Ataxic gait was observed after administration of cytosine arabinoside in a dose of 40 mg/kg (s.c.) on the second and third postnatal days. The falling index, the ratio of the number of inversions to spontaneous motor activity, is regarded as an index of ataxia. YM-14673 significantly reduced the falling index. YM-14673 was about 30 times more potent than TRH in reducing the ataxic activity. These results suggest that YM-14673 ameliorates the ataxic gait of cytosine arabinoside-treated mice.     

Effects of a new TRH analogue, YM-14673, on disturbance of passive avoidance learning in senescence-accelerated mice

Effects of a new TRH analogue, YM-14673 (N alpha-[[(S)-4-oxo-2-azetidinyl]carbonyl]-L-histidyl-L-prolinamide dihydrate), on disturbance of passive avoidance behavior were observed in senescence-accelerated mice (SAM). Latency of step-through in SAM-P/8/Ta (SAM-P/8, senescence-prone substrain) was significantly shorter than that in SAM-R/1/Ta (SAM-R/1, senescence-resistant substrain). Successive oral administration of YM-14673 (1 and 10 mg/kg) and TRH (10 mg/kg) for 3 weeks prolonged the shortened latency of step-through. These results suggest that YM-14673 is more potent than TRH in antiamnesic activities.     

Anticonvulsive properties of YM-14673, a new TRH analogue, in amygdaloid-kindled rats

Effects of YM-14673 (N alpha-[( (S)-4-oxo-2-azetidinyl]-carbonyl]-L- prolinamide dihydrate), a new TRH analogue, on the development of kindling and the duration of afterdischarge (AD) were observed in amygdaloid-kindled rats in comparison with those of TRH. The right medial amygdaloid nucleus was electrically stimulated once a day for establishment of kindling. YM-14673 and TRH were administered intraperitoneally 15 and 30 min prior to electrical stimulation from 2 days after the first stimulation, respectively, and the number of stimulations required for the development of generalized seizures was measured. YM-14673 (1 mg/kg) showed tendency to suppress the development of kindling (p less than 0.1), but TRH even at high dose (10 mg/kg) showed little effect on it. In addition, the experiment for the AD duration was conducted in full-kindled rats from one day after at least 3 reproducible generalized seizures were elicited by electrical stimulation of the medial amygdaloid nucleus once a day. Both YM-14673 (1 mg/kg) and TRH (10 mg/kg) administered 15 and 30 min prior to electrical stimulation of the amygdala, respectively, significantly shortened the AD duration in full-kindled rats. At these doses, both drugs desynchronized spontaneous cortical electroencephalogram (EEG) in normal rats. These results indicate that YM-14673 seems to possess anticonvulsive property in rats.     

促甲状腺素释放激素类似物YM14673对小鼠学习记忆的影响

采用小鼠跳台法评价促甲状腺素释放激素类似物YM14673(ip 1 mg·kg^-1) 对正常成年小鼠被动回避学习记忆成绩的影响. 结果表明YM14673对东莨菪碱， 氯霉素和乙醇造成的小鼠记忆获得,巩固及再现障碍均有明显的改善作用.     

Effects of a new analog of thyrotropin-releasing hormone, N alpha-[(S)-4-oxo-2-azetidinyl) carbonyl]-L-histidyl-L-prolinamide dehydrate (YM-14673) on spinal reflex potentials and flexor reflexes in spinalized rats

Experiments were performed on spinalized rats, transected at the Cl level. The intravenous administration of TRH and its analog YM-14673 (N alpha-[(S)-4-oxo-2-azetidinyl) carbonyl]-L-histidyl-L-prolinamide dehydrate) produced marked increases in the amplitude of mono- and polysynaptic reflex potentials and those of the withdrawal flexor reflexes. The effects of YM-14673 were stronger and longer-lasting than those of TRH. The stimulant action of TRH and YM-14673 on the flexor reflexes was not antagonized by prazosin, chlorpromazine, haloperidol or cyproheptadine, suggesting no involvement of the release of catecholamines or serotonin in the stimulant effects of TRH and its analog. Therefore, YM-14673 may be beneficial for the treatment of several spinal motor neuron diseases.     

The central action of pizotifen

The central action of the potential antidepressant drug pizotifen (Sandomigran) was studied in mice, rats and rabbits. Pizotifen in doses up to 10 mg/kg i.p. was ineffective in classic tests for antidepressant activity. It neither antagonized the effects of reserpine in rats (hypothermia, ptosis) nor potentiated the effects of amphetamine (in mice and rats), nialamide or L-dopa (in mice) on locomotor activity. However, its antidepressant activity was found in the despair test in rats.On the other hand, pizotifen inhibited the head twitch reaction induced by L-5-hydroxytryptophan in mice (ED₅₀=0.009 mg/kg, i.p.) and by 5-methoxytryptamine (+tranylcypromine) in rats (ED₅₀=0.45 mg/kg, i.p.). It also antagonized tryptamine-induced clonic convulsions of fore-paws in rats (ED₅₀=0.35 mg/kg, i.p.), and in doses of 5–10 mg/kg s.c. inhibited hyperthermia produced by LSD in rabbits. Finally, pizotifen (0.1–0.3 mg/kg, i.v.) inhibited or abolished LSD- or quipazine-induced stimulation of the hind limb flexor reflex of spinal rats; the above effect was not due to noradrenolytic action of the drug. These results suggest that pizotifen strongly blocks the central postsynaptic serotonin receptors.     

Effects of YM-14673, a new thyroid-releasing hormone analogue, on neurological deficits in stroke-prone spontaneously hypertensive rats

The effects of YM-14673, a new thyroid-releasing hormone (TRH) analogue (N alpha-[[(S)-4-oxo-2-azetidinyl]carbonyl]-L-histidyl-L-prolinamide dihydrate), on neurological deficits were examined in stroke-prone spontaneously hypertensive rats (SHRSP). The neurological deficits were evaluated for more than 21 days after stroke. Administration of YM-14673 was started the day stroke was observed and repeated daily for 3 weeks. YM-14673 (0.1 and 0.3 mg/kg i.p.) improved the neurological deficits and reduced mortality. These results demonstrate that YM-14673 mitigates cerebral ischemic changes in SHRSP.     

Comparative effects of thyrotropin releasing hormone,MK-771 and DN-1417 on morphine abstinence syndrome

The effect of thyrotropin releasing hormone (TRH) were compared with two of its analogs, l-N-(2-oxopiperidin-6-yl-carbonyl)-l-histidyl-l-thiazolidine-4-carboxamide (MK-771) and -butyrolactone-4-carboxyl-histidylprolineamide (DN-1417) on the abrupt and naloxone-precipitated abstinence symptoms in morphine-dependent male Swiss-Wester mice. Mice were made physically dependent on morphine by subcutaneous implantation for 3 days of a pellet containing 75 mg morphine free base. Control mice were implanted with placebo pellets. Intracerebral administration of TRH (10 ng-10 g per mouse) immediately after removal of placebo pellets had no effect on the basal temperature of mice. Mice implanted with morphine pellets exhibited a characteristic hypothermic response following the removal of the pellets. TRH at all doses employed prevented the hypothermia observed during abrupt withdrawal of morphine (pellet removal). DN-1417 and MK-771 (10 ng-10 g per mouse) on the other hand produced a short lived hyperthermic response in mice from which placebo pellets had been removed. However, both TRH analogs produced long-lasting antagonism of withdrawal hypothermia in mice from which morphine pellets had been removed. TRH and its analogs had no effect on the body weight loss observed during abrupt withdrawal of morphine. Intracerebral administration of 10 g TRH and its analogs inhibited the naloxone-induced jumping response as evidenced by increases in naloxone ED₅₀ values to elicit this response. It is concluded that TRH and its analogs may be useful in combating some of the withdrawal symptoms in opiate-dependent subjects.     

Effects of thyrotropin-releasing hormone on behavioral disturbances in middle cerebral artery-occluded rats

The effects of thyrotropin releasing hormone (TRH) on behavioral and histological changes were studied in rats subjected to left middle cerebral artery occlusion. The drug was given i.p. once or several times a day from 1 week after occlusion for 2 weeks. A single administration of TRH (1 and 10 mg/kg) did not affect the neurological deficits, but recovery of the deficits was accelerated by multiple administration (7 times a day) of TRH and single administration (once a day) of YM-14673 (N alpha-[[(S)-4-oxo-2-azetidinyl]carbonyl]-L-histidyl-L-prolinamide dihydrate), a new TRH analogue with a longer half-life. Both YM-14673 and single (1 and 10 mg/kg) and multiple administration of TRH ameliorated the disturbance of passive avoidance learning. Neuronal degeneration in the cerebral cortex and striatum was not influenced by the administration of TRH. Thus, we found that neurological deficits and disturbance of passive avoidance learning behavior in middle cerebral artery-occluded rats could be ameliorated by administration of TRH.     

促甲状腺素释放激素(TRH)类似物YM14673对大鼠脑损伤并发脑水肿的作用

用雄性Wistar大鼠,采用Feeney等的落体撞击法造成左顶颅脑挫伤。动物随机分组,给于TRH类似物YM14673(0.1 mg·kg^-1或1.0 mg.kg^-1,ip)或等体积生理盐水。治疗组可明显地减轻脑水肿。     

Neuroleptic properties of cis-N-(1-benzyl-2-methylpyrrolidin-3-yl)-5-chloro-2-methoxy-4-methylaminobenzamide (YM-09151-2) with selective antidopaminergic activity

A new benzamide, cis-N-(1-benzyl-2-methylpyrrolidin-3-yl)-5-chloro-2-methoxy-4-methylaminobenzamide (YM-09151-2) exhibited more potent and longer-lasting inhibitory effects on apomorphine-induced behaviours (stereotyped behaviour, emesis and hypothermia), and methamphetamine-induced stereotyped behaviour, conditioned avoidance response and open field behaviour than either structurally similar benzamides (YM-0850 and sulpiride) or calssical neuroleptics [chlorpromazine(CPZ) and haloperidol(HPD)]. Such inhibitory effects of YM-09151-2 relative to cataleptogenicity were greater than those of CPZ and HPD. In contrast, sulpiride elicited few of the neuroleptic effects described above. YM-09151-2, a potent inhibitor for dopamine-sensitive adenylate cyclase (Ki: 3.0 nM) reduced, in a selective manner, the binding of [³H]dopamine to the dopamine D₁ receptor (Ki: 4.8 nM) associated with adenylate cyclase rather than to the dopamine D₂ receptor (Ki: 0.98 M) independent of adenylate cyclase. Sulpiride, on the contrary, inhibited only the binding to the dopamine D₂ receptor. CPZ and HPD antagonized [³H]dopamine non-selectively at the two distinct dopaminergic receptors. These results suggest that YM-09151-2 is a potent and long-lasting neuroleptic with a highly selective blocking action on the dopamine D₁ receptor.     

Further studies on (±)-YM-12617, a potent and selective α1-adrenoceptor antagonist and its individual optical enantiomers

Summary YM-12617, 5-[2-[[2-(o-ethoxyphenoxy)ethyl]amino]propyl]-2-methoxybenzenesulfonamide HCl is structurally novel, an extremely potent and highly selective ₁-adrenoceptor antagonist. An asymmetric center exists at the -carbon atom in the phenethylamine portion of YM-12617, therefore two optical enantiomers exist. -Adrenoceptor blocking properties and hypotensive activities of YM-12617 and its enantiomers have been compared in vitro and in vivo. 1. In the isolated rabbit aorta, R(–)- and S(+)-YM-12617 competitively antagonized phenylephrine-induced contraction with pA₂ values of 9.95 and 7.69, respectively. Although R(–)- and S(+)-YM-12617 were also competitive antagonists toward UK-14,304 at prejunctional ₂-adrenoceptors in the isolated guinea-pig ileum, the affinities of R(–)-YM-12617 (pA₂ = 6.18) and S(+)-YM-12617 (pA₂ = 5.64) for these receptors were 5,900 and 110 times lower than those displayed for postjunctional ₁-adrenoceptors in the isolated rabbit aorta. 2. R(–)- and S(+)-YM-12617 displaced both ³H-prazosin and ³H-idazoxan binding to rat brain membranes; however, the affinities of the R(–)- and S(+)-enantiomers for ₁-adrenoceptors (pK_i = 9.95 and 7.83, respectively) were 21,000 and 72 times higher than those for ₂-adrenoceptors (pK _i = 5.62 and 5.97), respectively. 3. Based on pA₂ values obtained in the isolated tissues and pK _i values in the binding assays, R(–)-YM-12617 was 132–182 times more potent than S(+)-YM-12617 as an antagonist at ₁-adrenoceptors. In contrast, the R(–)- and S(+)-enantiomers were similar in potency at blocking ₂-adrenoceptors. 4. In normotensive pithed rats, R(–)- and S(+)-YM-12617 preferentially antagonized the ₁-adrenoceptor mediated pressor effect of phenylephrine with DR₁₀ values of 1.38 and 705 g/kg i. v., respectively, although a high dose (3,000 g/kg i.v.) also inhibited the effect of UK-14,304 at postjunctional ₂-adrenoceptors. R(–)-YM-12617 exhibited an over 2,000-fold selectivity for postjunctional ₁-adrenoceptors, and R(–)-YM-12617 was over 500 times more potent than S(+)-YM-12617 in antagonizing postjunctional ₁-adrenoceptors based on DR₁₀ values. 5. In anesthetized rats, R(–)- and S(+)-YM-12617 dose-dependently produced hypotension with ED₂₀ values, doses required decreased mean blood pressure by 20%, of 0.64 and 61 g/kg i. v., respectively. R(–)-YM-12617 exerted a 95 times more potent hypotensive activity than S(+)-YM-12617, and its isomeric activity ratio was consistent with that for ₁-adrenoceptors but not ₂-adrenoceptors. 6. The present results suggest that the high stereoselectivity of the optical enantiomers of YM-12617 is in the ₁-adrenoceptor, but not in the ₂-adrenoceptor, and their antagonist potency for ₁-adrenoceptors is likely to contribute to the hypotensive effect. Send offprint requests to K. Honda     

Synthesis and central nervous system actions of thyrotropin-releasing hormone analogues containing a dihydroorotic acid moiety

A series of thyrotropin-releasing hormone (TRH) analogues in which the pyroglutamic acid residue was replaced by (S)-4,5-dihydroorotic acid (Dio-OH) and the related derivatives were prepared. Their central nervous system actions based on spontaneous locomotor activity, antagonistic effect on reserpine-induced hypothermia, and antagonistic effect on pentobarbital anesthesia were evaluated and the structure-activity relationships are discussed. Of these, (1-methyl-(S)-4,5-dihydroorotyl)-L-histidyl-L-prolinamide (14b) showed the most potent activities, which were 30-90 times greater than those of TRH. Moreover, the thyrotropin-releasing activity of 14b was about 50 times weaker than that of TRH, and compound 14b (TA-0910) was selected as a potent candidate.     

Species differences in the metabolism of di(2-ethylhexyl) phthalate (DEHP) in several organs of mice, rats, and marmosets

To clarify species differences in the metabolism of di(2-ethylhexyl) phthalate (DEHP) we measured the activity of four DEHP-metabolizing enzymes (lipase, UDP-glucuronyltransferase (UGT), alcohol dehydrogenase (ADH), and aldehyde dehydrogenase (ALDH)) in several organs (the liver, lungs, kidneys, and small intestine) of mice (CD-1), rats (Sprague–Dawley), and marmosets (Callithrix jacchus). Lipase activity, measured by the rate of formation of mono(2-ethylhexyl) phthalate (MEHP) from DEHP, differed by 27- to 357-fold among species; the activity was highest in the small intestines of mice and lowest in the lungs of marmosets. This might be because of the significant differences between Vmax/Km values of lipase for DEHP among the species. UGT activity for MEHP in the liver microsomes was highest in mice, followed by rats and marmosets. These differences, however, were only marginal compared with those for lipase activity. ADH and ALDH activity also differed among species; the activity of the former in the livers of marmosets was 1.6–3.9 times greater than in those of rats or mice; the activity of the latter was higher in rats and marmosets (2–14 times) than in mice. These results were quite different from those for lipase or UGT activity. Because MEHP is considered to be the more potent ligand to peroxisome proliferator-activated receptor involved in different toxic processes, a possibly major difference in MEHP-formation capacity could be also considered on extrapolation from rodents to humans.     

Pharmacological study of TA-0910, a new thyrotropin-releasing hormone (TRH) analog, (I): Effects on the central nervous system by oral administration

Effects of orally administered TA-0910, a new thyrotropin-releasing hormone (TRH) analog, on the central nervous system (CNS) were investigated and compared with those of TRH. TA-0910 shortened the duration of pentobarbital-induced sleep and antagonized reserpine-induced hypothermia at 0.3 mg/kg or more in mice. TA-0910 enhanced the spontaneous motor activity at the higher dose of 30 mg/kg in mice. The drug also activated acute spontaneous EEGs in rabbits at 1 mg/kg. TRH produced these effects at about 100 times higher doses than TA-0910. In antagonizing pentobarbital-induced sleep, the dose ratios of i.v. versus p.o. of TA-0910 and TRH were about 1/10 and 1/100, respectively. The duration of the antagonistic action of TA-0910 on pentobarbital-induced sleep in mice was about 8 times longer than that of TRH when administered orally as well as intravenously. These potent and long-acting TA-0910 effects on the CNS are discussed in connection with its biotransformation.     

Role of nitric oxide in penile erection and yawning induced by 5-HT1c receptor agonists in male rats

The effect of the intracerebroventricular (i.c.v.) administration of N^G-nitro-l,-arginine methyl ester and N^G-monomethyl-l.-arginine, two inhibitors of nitric oxide (NO) synthase, on penile erection and yawning induced by 1-(3-chlorophenyl)-piperazine (m-CPP)- and N-(3-trifluoromethylphenyl)-piperazine (TFMPP), two selective 5HT_1c receptor agonists, was studied in male rats. Both NO synthase inhibitors (50–500 g i.c.v.) prevented dose-dependently the behavioural responses induced by m-CPP (0.5 mg/kg s.c.) or by TFMPP (I mg/kg s.c.), but N^G-nitro-l-arginine methyl ester was about 4–5 times more potent than N^G-monomethyl-l,-arginine. The D-isomer of N_G-monomethyl-l-arginine, which does not inhibit nitric oxide synthase, was ineffective. The inhibitory effect of N^G-nitro-l-arginine methyl ester on m-CPP- and TFMPP-induced responses was prevented by the administration of l-arginine (1 mg i.c.v.). In contrast, N^G-nitro-l-arginine methyl ester (20 g) was ineffective when injected in the paraventricular nucleus of the hypothalamus, a brain area that plays a key role in the expression of these behavioural responses. m-CPP- and TFMPP-induced penile erection and yawning was prevented also by the i.c.v. administration of LY 83583 (50–200 g) or methylene blue (50–400 g), two inhibitors of guanylate cyclase but not by reduced hemoglobin (50–400 g), a NO scavenger. The results suggest that central nitric oxide is involved in the expression of penile erection and yawning induced by 5-HT_1c receptor agonists.